Literature DB >> 34216957

Genetic determinants of multiple myeloma risk within the Wnt/beta-catenin signaling pathway.

Alem A Belachew1, Xifeng Wu1, Rashida Callender1, Rosalie Waller2, Robert Z Orlowski3, Celine M Vachon4, Nicola J Camp2, Elad Ziv5, Michelle A T Hildebrandt6.   

Abstract

BACKGROUND: Aberrant Wnt/beta-catenin pathway activation is implicated in Multiple Myeloma (MM) development, but little is known if genetic variants within this pathway contribute to MM susceptibility.
METHODS: We performed a discovery candidate pathway analysis in 269 non-Hispanic white MM cases and 272 controls focusing on 171 variants selected from 26 core genes within the Wnt/beta-catenin pathway. Significant candidate variants (P < 0.05) were selected for validation in internal and external non-Hispanic white populations totaling 818 cases and 1209 controls. We also examined significant variants in non-Hispanic black and Hispanic case/control study populations to identify potential differences by race/ethnicity. Possible biological functions of candidate variants were predicted in silico.
RESULTS: Seven variants were significantly associated with MM risk in non-Hispanic whites in the discovery population, of which LRP6:rs7966410 (OR: 0.57; 95 % CI: 0.38-0.88; P = 9.90 × 10-3) and LRP6:rs7956971 (OR: 0.64; 95 % CI: 0.44-0.95; P = 0.027) remained significant in the internal and external populations. CSNK1D:rs9901910 replicated among all three racial/ethnic groups, with 2-6 fold increased risk of MM (OR: 2.40; 95 % CI: 1.67-3.45; P = 2.43 × 10-6 - non-Hispanic white; OR: 6.42; 95 % CI: 2.47-16.7; P = 3.14 × 10-4 - non-Hispanic black; OR: 4.31; 95 % CI: 1.83-10.1; P = 8.10 × 10-4 - Hispanic). BTRC:rs7916830 was associated with a significant 37 % and 24 % reduced risk of MM in the non-Hispanic white (95 % CI: 0.49-0.82; P = 5.60 × 10-4) and non-Hispanic Black (95 % CI: 0.60-0.97; P = 0.028) population, respectively. In silico tools predicted that these loci altered function through via gene regulation.
CONCLUSION: We identified several variants within the Wnt/beta-catenin pathway associated with MM susceptibility. Findings of this study highlight the potential genetic role of Wnt/beta-catenin signaling in MM etiology among a diverse patient population.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Disparities; Genetic variation; Myeloma; Susceptibility; Wnt/beta-catenin

Mesh:

Substances:

Year:  2021        PMID: 34216957      PMCID: PMC8351401          DOI: 10.1016/j.canep.2021.101972

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.890


  47 in total

1.  The human genome browser at UCSC.

Authors:  W James Kent; Charles W Sugnet; Terrence S Furey; Krishna M Roskin; Tom H Pringle; Alan M Zahler; David Haussler
Journal:  Genome Res       Date:  2002-06       Impact factor: 9.043

2.  Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups.

Authors:  Sikander Ailawadhi; Ibrahim T Aldoss; Dongyun Yang; Pedram Razavi; Wendy Cozen; Taimur Sher; Asher Chanan-Khan
Journal:  Br J Haematol       Date:  2012-04-26       Impact factor: 6.998

Review 3.  The Wnt/β-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer.

Authors:  Taj D King; Mark J Suto; Yonghe Li
Journal:  J Cell Biochem       Date:  2012-01       Impact factor: 4.429

4.  In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.

Authors:  Samantha Pozzi; Mariateresa Fulciniti; Hua Yan; Sonia Vallet; Homare Eda; Kishan Patel; Loredana Santo; Diana Cirstea; Teru Hideshima; Linda Schirtzinge; Stuart Kuhstoss; Kenneth C Anderson; Nikhil Munshi; David Scadden; Henry M Kronenberg; Noopur Raje
Journal:  Bone       Date:  2013-01-17       Impact factor: 4.398

5.  Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment.

Authors:  Nicola Giuliani; Francesca Morandi; Sara Tagliaferri; Mirca Lazzaretti; Gaetano Donofrio; Sabrina Bonomini; Roberto Sala; Marcellina Mangoni; Vittorio Rizzoli
Journal:  Cancer Res       Date:  2007-08-15       Impact factor: 12.701

6.  Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.

Authors:  Claire M Edwards; James R Edwards; Seint T Lwin; Javier Esparza; Babatunde O Oyajobi; Brandon McCluskey; Steven Munoz; Barry Grubbs; Gregory R Mundy
Journal:  Blood       Date:  2007-12-19       Impact factor: 22.113

Review 7.  The pathogenesis of the bone disease of multiple myeloma.

Authors:  Claire M Edwards; Junling Zhuang; Gregory R Mundy
Journal:  Bone       Date:  2008-02-21       Impact factor: 4.398

8.  BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.

Authors:  Charles G Mullighan; Christopher B Miller; Ina Radtke; Letha A Phillips; James Dalton; Jing Ma; Deborah White; Timothy P Hughes; Michelle M Le Beau; Ching-Hon Pui; Mary V Relling; Sheila A Shurtleff; James R Downing
Journal:  Nature       Date:  2008-04-13       Impact factor: 49.962

9.  Illegitimate WNT signaling promotes proliferation of multiple myeloma cells.

Authors:  Patrick W B Derksen; Esther Tjin; Helen P Meijer; Melanie D Klok; Harold D MacGillavry; Marinus H J van Oers; Henk M Lokhorst; Andries C Bloem; Hans Clevers; Roel Nusse; Ronald van der Neut; Marcel Spaargaren; Steven T Pals
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-05       Impact factor: 11.205

10.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

Authors:  Erming Tian; Fenghuang Zhan; Ronald Walker; Erik Rasmussen; Yupo Ma; Bart Barlogie; John D Shaughnessy
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.